SeaStar Medical Receives Canadian Patent Claiming Coverage of its Selective Cytopheretic Device Technology
Shots:
- SeaStar Medical has received patent no. 2814586 by the Canadian Intellectual Property Office for its Selective Cytopheretic Device (SCD) technology
- The Canadian patent, titled Cytopheretic Cartridge and Use Thereof, claims coverage of SCD cartridges for the treatment of activated leukocytes & activated platelets and their utilization in processing activated leukocytes and platelets
- The SCD technology employs the body’s immune system to heal and can be used with extracorporeal therapies incl. dialysis or continuous kidney replacement therapy. It targets toxic neutrophils to offer a new approach to systemic inflammatory response syndrome
Ref: Seastar | Image: Seastar
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
